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Angiotensin II type 1 receptor blockade to control blood pres- Epidemiological studies have identified a rise in blood
sure in postmenopausal women: Influence of hormone replace- pressure (BP), body mass index (BMI), blood glucose
ment. and lipid levels with age, this in turn being associated withBackground. Hypertension is twice as common in post-
an increased prevalence of hypertension (HT), obesity,menopausal than in premenopausal women. This study evalu-
ated the effectiveness of a blockade of the renin-angiotensin- diabetes and hypercholesterolemia [1]. These increases
aldosterone system (RAAS) with candesartan cilexetil (CC) to are more manifest after the fourth decade of life, and
control blood pressure (BP) in hypertensive menopausal women, the values tend to be higher among women than in men.and the influence of hormone replacement therapy (HRT).
In this context, cardiovascular disease is the first causeMethods. This was designed as a prospective, open-label
of death among postmenopausal women in the industri-and non-comparative study. Included were 618 hypertensive
menopausal women grade I/II according to the Sixth Report alized world [2, 3]. Hypoestrogenism secondary to the
of the Joint National Committee (VI-JNC), with an average postmenopausal decrease in ovarian function favors the
age 52 4.7 years (95% CI 52.3-53.0) and with a last menstrual
occurrence of obesity, insulin resistance, dyslipidemia,period (LMP) at least one year before. BP was determined by
HT and hemostatic abnormalities. The slope of the risingmeasurement in four visits during six months of follow-up,
according to the recommendations of the OMS/SIH. Optimal BP curve and the risk of developing HT has been shown
control of BP was considered as BP 140/90 mm Hg. to be 2.2 times greater among postmenopausal than in
Results. A statistically significant decrease in systolic (SBP;
premenopausal women [4]. HT in menopause is associ-19.9  11.2) and diastolic (DBP; 11.5  7.3) blood pressure
ated with an important accumulation of metabolic riskmm Hg values was observed (P  0.01). The control of BP
increased significantly over time to 61.2% (P 0.01). In multi- factors. In this context, the lack of estrogens favors sym-
variate analysis, only age was associated with control of BP pathetic hyperactivity, particularly under conditions of
(  0.062; P  0.004). Of the women not controlled in the
stress [5]. In addition to peripheral vasoconstriction, thesecond visit, 12.5 mg of hydrochlorothiazide (HCTZ) were
increase in sympathetic tone stimulates renal tubularadded to 31.5% (N 122), with 80% more BP control achieved
in visit 3 than in the non-supplement group (OR  1.8; 95% sodium reabsorption, thus favoring salt sensitivity [6].
CI 1.04–3.05; P  0.03). One hundred and three (16.7%) pa- Hypoestrogenism likewise reduces nitric oxide (NO) ac-
tients were receiving HRT for 2.01 2.23 years (95% CI 1.55–
tivity and increases the response to endothelin [7] and2.46). HRT did not affect the control of BP. No severe adverse
myocyte growth [8]. Such endothelial dysfunction re-reactions were reported.
Conclusions. Candesartan cilexetil significantly reduced SBP duces natriuresis mediated by the NO deficiency and
and DBP and increased control (61.2%) of BP in hyperten- induces glomerular vasoconstriction through endothelinsive menopausal women. Only age had an inverse association
action [9]. Blockade of the renin-angiotensin-aldosteronewith control of BP. In this study, HRT did not affect the control
system (RAAS) by an angiotensin II type 1 receptorof BP.
blocker (ARB) would be able to control BP in these
situations and improve the negative incidence of cardio-Key words: hypertension, post-menopausal women, renin-angiotensin-
aldosterone system, candesartan cilexetil, ARB, HRT. vascular risk factors (CVRF) associated with meno-
pause, yielding an improved metabolic profile and more- 2002 by the International Society of Nephrology
S-36
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Table 1. Inclusion and exclusion criteria of the diastolic blood pressure (DBP) and basic laboratory pa-
participants in this study
rameters. Possible HRT was recorded, together with the
Inclusion criteria type and duration of such treatment.
1. Hypertensive women aged 45 to 55 years (inclusive) Blood pressure was determined in the Health Care2. Blood pressure in stages 1 or 2 of the VI-JNC (SBP 140–179
Centers by physicians and/or nursing personnel, usingand/or DBP 90–109 mm Hg)
3. Cessation of menstruation at least one year before mercury sphygmomanometers and cuff sizes adapted to
4. Informed consent the circumference of the arm (recommendations WHO/Exclusion criteria
HIS) [12]. On all visits two BP measurements were made,1. Patients with severe (SBP 180 and/or DBP 110 mm Hg) or
secondary HT identified at any time during the study under standard conditions, after which BP was classified
2. Allergy or contraindication to ARB and/or hydrochlorothiazide as either stage 1 (SBP 140 to 159 and/or DBP 903. Recent cerebrovascular stroke or myocardial infarction
to 99 mm Hg) or 2 (SBP 160 to 179 and/or DBP(four previous months)
4. Severely impaired renal function (creatinine 2.5 mg/dL and 100 to 109 mm Hg), according to the recommenda-
potassemia 6 mEq/L) tions of the VI-JNC. Adequate BP control was defined5. Severely impaired liver function (liver enzymes 3-fold above the
as SBP 140 mm Hg and DBP 90 mm Hg.upper reference limit)
6. Patient decision The start of treatment was recommended with 16 mg
7. Any clinical, mental or social factor that according to investigation of CC at the baseline visit, followed by the addition ofcriterion complicates or makes patient follow-up impossible
12.5 mg of HCTZ in the event adequate BP control was
not achieved. However, it was left to the investigator to
decide the best approach for each individual patient,
according to clinical criteria. The aim of this decisionover affording good renal protection [10]. The aim of
was to ensure medical care according to routine practice.the present study was to evaluate the effectiveness of an
The sample size was calculated by estimating a per-ARB, candesartan cilexetil (CC) in controlling BP in
centage control of 50% in the global study series, withpostmenopausal women, when used in the context of
a precision of 4% for a 95% confidence interval (95%routine clinical practice, and assess the influence of hor-
CI). This involved a sample size of 601 patients. Descrip-mone replacement therapy (HRT).
tive statistics were determined based on calculation of
the means and standard deviations (SD) for the continu-
METHODS ous variables and proportions for categorical variables.
A prospective, multicenter, open label and non-com- The initial and final mean values were contrasted by the
parative observational study was designed. The field work Student t test for paired samples in the case of continuous
took place between June 1999 and June 2000. The inclu- variables with a normal distribution, and by the Wilcoxon
sion period was six months, and the patient observation nonparametric test in the case of variables without nor-
and follow-up period comprised a further six months. mal distribution. Dichotomic categorical variables were in
Consecutive sampling was made of 618 hypertensive turn analyzed by the McNemar test for paired samples
menopausal women as they presented for consultation, and the chi-square test in the rest of cases. A multivariate
HT corresponding to stage 1 or 2 according to the criteria analysis involving logistic regression models was performed
of the Sixth Report of the Joint National Committee to evaluate the association of baseline variables to BP
(VI-JNC) [11], with a mean age of 52.7 4.7 years (95% control. A 95% confidence level was established. The
CI 52.3–53.0) and their last menstrual period (LMP) at SPSS version 10.0 statistical package for MS Windows
least one year before. Once the investigator decided was used throughout (SPSS, Inc., Chicago, IL, USA).
treatment with fixed daily doses of CC (16 mg), and the
patients met all the inclusion criteria and none of the
RESULTSexclusion criteria, informed consent was obtained fol-
A total of 121 primary care physician-investigatorslowed by inclusion in the study (Table 1).
participated in the study, finally recruiting a total ofThe patients were followed-up on for six months, with
618 women, of which 586 (94.8%) completed the pro-an initial inclusion visit and three follow-up visits after
grammed visits and were included in the analysis of re-one, three and six months. At the end of follow-up,
sults. The mean age was 52.7  4.4 years (95% CI 52.3–586 women (94.8%) were seen to have completed the
53.0), and the time elapsed from the diagnosis of HTprogrammed visits and were subsequently included in
was 5.3  4.5 years (95% CI 4.7–5.8). The BMI wasthe analysis of results. The investigators completed the
28.6  4.4 kg/m2 (95% CI 28.2–28.9). A total of 103case report form (CRF) for each patient by direct inter-
women were receiving HRT for an average of 2.0  2.2view, recording the following variables: age, sex, weight,
years (95% CI 1.5–2.5). In turn, 32.3% of the hyperten-height, body mass index (BMI), family history of cardio-
sive patients presented no other associated CVRF, whilevascular disease, concomitant diseases, year of diagnosis
of HT, heart rate (HR), systolic blood pressure (SBP), 35.3% presented one additional factor and 26.9% had
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Table 2. Global (and individual BP percentage) control values at each study visit
Basal (N  618) 1st month (N  598) 3rd month (N  591) 6th month (N  586)
SBP mm Hg % control 156.410.4 (2.9) 143.110.7 (34.5) 138.19.5 (59.2) 136.510.1 (65.5)
DBP mm Hg % control 94.56.7 (15.5) 86.96.4 (61.1) 83.85.7 (81.4) 83.05.7 (87.2)
BP % control 0 30.4% 54.9% 61.2%
HR bpm 77.08.0 75.28.4 74.87.6 74.47.7
HCTZ 0 21.4% 25.6% 25.1%
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; HCTZ, hydrochlorothiazide, percent used at each study point.
Fig. 1. Course of the mean (A) systolic and
(B) diastolic blood pressure (SBP and DBP)
values on the different follow-up visits of the
study. (C ) Time course of the mean percent-
age SBP () and DBP () control values and
global BP () control (SBP 140 mm Hg
and/or DBP 90 mm Hg) in the course of the
24 weeks of follow-up (means  standard de-
viation, SD). *P  0.01, †P  0.01 vs. Visit 1
and Visit 2.
more than one (dyslipidemia in 34.7%, a family history than in the subgroup not administered HCTZ (OR 
of cardiovascular disease in 31.2%, smoking in 18.9%, 1.8; 95% CI 1.04–3.05; P  0.03), adjusting for SBP and
and diabetes in 15.7%). DBP on visit 2 (Fig. 2).
The baseline values of the study sample were: SBP One hundred and three women started the study with
156  10.4 mm Hg and DBP 94.5  6.7 mm Hg. During HRT: 33% with estrogens and the remaining 67% in com-
follow-up, the SBP deceased (19.9  11.2 mm Hg), as bination with progestogens. The mean duration of HRT
did the DBP (11.5  7.3 mm Hg; P  0.01; Table 2). was 2.01  2.23 years (95%CI 1.55–2.46). The decrease
The percentage of BP control (140/90 mm Hg) on the in SBP and DBP, as well as BP control, was similar
last visit was 61.2% (P 0.01). DBP control was greater between the groups with or without HRT (Fig. 3). There
(by about 20%) on all visits than SBP control (Fig. 1). were no differences according to the type of HRT admin-
The multivariate logistic regression analysis showed pa-
istered. No relationship was observed between patients
tient age to be the only variable inversely related to BP
with HRT and those administered HCTZ supplementscontrol on the last visit (b  0.062; P  0.004).
(chi-square  3.57; P  0.06). Of the 32 patients (5.2%)On the second visit after one month of follow-up, 387
who failed to complete the study, the loss to follow-upwomen (64.7%) showed BP values of 140/90 mm Hg.
was attributable to a change in address in 43.7% of cases,Treatment was supplemented with 12.5 mg of hydrochlo-
non-presentation in 31.3%, BP normalization in 6.2%,rothiazide (HCTZ) daily in 31.5% (N  122) of these
and adverse reactions in 18.7%. Only 6 adverse effectswomen, while the rest (N  265) continued with the
leading to patient dropout were reported and registeredmonotherapeutic regimen. On visit 3, a significant reduc-
(headache in two cases, epigastric pain in two cases, dizzi-tion in BP was observed in both groups (P  0.05). In
ness in one, and allergic reactions in another); no seriousthe subgroup to which 12.5 mg of HCTZ was added,
80% more BP control was achieved on the third visit adverse event been reported.
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Fig. 3. Blood pressure control in postmenopausal women with HRT
() or without HRT () during successive visits.
Calcium antagonists as monotherapy, and combination
diuretics, are the most widely used drugs for treating HT
in postmenopausal women [15]. Few data are available
in the literature on the efficacy of ARB in monotherapy
or in combination with a thiazide diuretic. In our series
the effectiveness of CC as monotherapy and/or in combi-
nation with 12.5 mg of HCTZ for the control of BP
reached 61%. This important discrepancy is probably at-
tributable to the reduced mean age and duration of HT
in the postmenopausal women of our series. The crite-
rion used for associating CC to the thiazide diuretic (in
25% of the sample) correctly reproduces routine medical
practice in our setting, since the physicians decided on
the drug combination based on their own clinical criteriaFig. 2. Time course of the mean global percentage BP control (A, SBP
140 mm Hg and/or B, DBP 90 mm Hg) throughout the 24 weeks and knowledge.
of follow-up of the study, in the subgroups of patients with and without One of the classical questions concerning the indica-
hormone replacement therapy (HRT). Data are means  standard tion of HRT in hypertensive climacteric women isdeviation (SD). Symbols are: () with hydrochlorothiazide (HCTZ),
whether such therapy causes increased BP or reducesN  122; () without HCTZ, N  265. *P  0.01 in both subgroups.
In (C ), the odds ratio  1.8, 95% CI  1.04-3.05, and P  0.03. the action of the antihypertensive treatment provided.
In the PEPI study [16], no significant differences were
obtained in BP after three years of HRT administered
DISCUSSION according to different regimens.
A recent meta-analysis of the effect of HRT on BPThis study was conducted in primary care clinics, in-
concluded that, in general, estrogens at the doses usedvolving a cohort of hypertensive women with the LMP
in menopause do not increase BP [17]. Nevertheless, theat least one year before.
evaluation of the effect of estrogens upon BP should beThe main limitation of the study is the lack of a control
individualized according to the type of estrogen provided,group. Naturalistic studies such as the present survey,
the administration route involved, and the dose prescribed.with scantly limiting inclusion and exclusion criteria, ob-
While synthetic estrogens used at high doses in oral con-jectively reflect the situation of routine clinical practice
traceptives can elevate BP by increasing the renin sub-by including patients representative of the population
strate [18], natural estrogens (fundamentally 17--estra-visiting the clinic, since routine medical practice is not
diol) at low doses and preferentially administered via
modified. the transdermal route (50 	g) appear to reduce BP in
The sample analyzed reflects the frequent association both normotensive and hypertensive women [18–20].
of other CVRF in hypertensive postmenopausal women, The development of HT after starting HRT is uncom-
with the particular presence of dyslipidemia and diabe- mon, and is very probably related to the use of synthetic
tes, and confirms the previously established observation progestogens, since most of the latter are not specific for
that HT in climacteric women is characterized by meta- progesterone receptors and can variably bind to andro-
bolic deterioration [13, 14]. In our study only one-third gen, estrogen and glucocorticoid receptors. For this rea-
of the women had no other associated CVRF. son it is advisable to use non-androgenic gestagens,
Hypertension in menopause is associated with in- which may exert anti-mineralocorticoid action due to the
creased morbidity-mortality, and its control is thus essen- high affinity of progesterone for aldosterone receptors
tial. As in the general population, the percentage HT [21]. Another mechanism that may lead to HT would be
estrogen inhibition of the reuptake of noradrenaline re-control in menopausal women is low (around 36%) [15].
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